<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136006">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01690780</url>
  </required_header>
  <id_info>
    <org_study_id>R-11-340</org_study_id>
    <secondary_id>18091</secondary_id>
    <nct_id>NCT01690780</nct_id>
  </id_info>
  <brief_title>Oral Morphine Versus Ibuprofen</brief_title>
  <official_title>Oral Morphine Versus Ibuprofen for Post-fracture Pain Management in Children: a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naveen Poonai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children 5-17 years of age who have sustained a non-operative distal forearm (radius and/or
      ulna) or clavicular fracture will be randomized to receive either ibuprofen or oral morphine
      as needed for pain relief for the first 24 hours following discharge from the emergency
      department. Pain will be assessed using the self-report Faces pain scale revised (FPS-R).
      We hypothesize that oral morphine will result in greater pain relief than ibuprofen.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Faces Pain scale - revised</measure>
    <time_frame>30 minutes post intervention compared to baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome variable is the pre-post intervention difference in pain scores as measured by self-reported Faces Pain Scale - Revised (FPS-R) for the first 24 hours post-fracture management following the as needed administration of the study drugs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acetaminophen doses</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary outcome variable is the number of breakthrough acetaminophen doses required/taken by the participant for the first 24 hours post-fracture management</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Upper Extremity Fractures</condition>
  <condition>Analgesia Post Fracture</condition>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral morphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral morphine</intervention_name>
    <description>oral morphine 0.5 mg/kg (max 10 mg) every 6 hours as needed for 24 hours</description>
    <arm_group_label>Oral morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 4 doses) for 24 hours following discharge from the emergency department</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Exclusion Criteria:

          -  patients with known hypersensitivity to either ibuprofen or morphine

          -  chronic users of NSAIDS or opioids

          -  fractures requiring operative management

          -  associated injuries requiring analgesia

          -  poor English fluency

          -  pregnancy

        Inclusion Criteria:

          -  All patients aged 5 to 17 years with a non-operative forearm or distal radius
             fracture
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naveen Poonai, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawson Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Health Sciences Center</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naveen P Poonai, MD</last_name>
      <phone>519 685 8500</phone>
      <phone_ext>52011</phone_ext>
      <email>poonai@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Rod Lim, MD</last_name>
      <phone>519 685 8500</phone>
      <phone_ext>52011</phone_ext>
      <email>rod.lim@lhsc.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Naveen P Poonai, MD MSc FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 19, 2012</lastchanged_date>
  <firstreceived_date>September 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Naveen Poonai</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>fracture</keyword>
  <keyword>pediatric</keyword>
  <keyword>oral morphine</keyword>
  <keyword>ibuprofen</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
